Advertisement

Age: A Criterion to Offer Surgical Treatment as a Cytoreductive Tool for Malignant Primary Brain Tumour?

  • Joseph H. McAbeeEmail author
  • Aida K. Golahmadi
  • Colin Watts
Chapter

Abstract

Elderly glioblastoma patients are often not considered for gross total resection, the validated optimal surgical treatment, due to concern about preoperative comorbidities or potential postoperative complications. However, recent studies suggest that cytoreductive surgery can be well tolerated and improve quality of life, progression free survival, and overall survival in the elderly population. Therefore, neurosurgeons must consider more holistic metrics, such as comprehensive geriatric assessments, when making operative decisions and should make a more concerted effort to include elderly patients in clinical trials.

Keywords

Malignant brain tumour Age Surgery 

Supplementary material

438026_1_En_4_MOESM1_ESM.docx (227 kb)
Table 1 List of articles used for analysis (DOCX 26 kb)

References

  1. 1.
    Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncology. 2012;14(Suppl 5):v1–49.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Louis DN, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Patel AP, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344:1396–401.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Sottoriva A, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013;110:4009–14.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro-Oncology. 2010;12:520–7.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Ostrom QT, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro-Oncology. 2018;20:iv1–iv86.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    McGirt MJ, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110:156–62.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25:1824–31.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Owusu C, Berger NA. Comprehensive geriatric assessment in the older cancer patient: coming of age in clinical cancer care. Clin Pract. 2014;11:749–62.CrossRefGoogle Scholar
  11. 11.
    Kirkhus L, et al. Geriatric assessment is superior to oncologists’ clinical judgement in identifying frailty. Br J Cancer. 2017;117:470–7.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    McGowan J, et al. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40–6.CrossRefGoogle Scholar
  13. 13.
    Guyatt G, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–94.CrossRefGoogle Scholar
  14. 14.
    Balshem H, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–6.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Vuorinen V, Hinkka S, Färkkilä M, Jääskeläinen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir. 2003;145:5–10.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Scott JG, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer. 2012;118:5595–600.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Pirracchio R, et al. One-year outcome after neurosurgery for intracranial tumor in elderly patients. J Neurosurg Anesthesiol. 2010;22:342–6.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Zouaoui S, et al. Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France. Neurosurg Rev. 2014;37:415–24.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Seicean A, et al. Short-term outcomes of craniotomy for malignant brain tumors in the elderly. Cancer. 2013;119:1058–64.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Bander ED, Magge R, Ramakrishna R. Advances in glioblastoma operative techniques. World Neurosurg. 2018;116:529–38.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Stummer W, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392–401.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Holdhoff M, Chamberlain MC. Controversies in the treatment of elderly patients with newly diagnosed glioblastoma. J Natl Compr Cancer Netw. 2013;11:1165–72.CrossRefGoogle Scholar
  23. 23.
    Weller M, Wick W. Are we ready to demystify age in glioblastoma? Or does older age matter in glioblastoma? Neuro-Oncology. 2011;13:365–6.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Batchelor TT, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res. 2004;10:228–33.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Hartmann C, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120:707–18.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Nghiemphu PL, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72:1217–22.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Malmström A, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13:916–26.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Keime-Guibert F, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356:1527–35.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Malmstrom A, et al. Glioblastoma (GBM) in elderly patients: a randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ). J Clin Oncol. 2010;28:LBA2002.CrossRefGoogle Scholar
  31. 31.
    Wick W, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707–15.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Fiorentino A, et al. Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials? Am J Clin Oncol. 2015;38:23–7.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Rusthoven CG, et al. Combined-modality therapy with radiation and chemotherapy for elderly patients with glioblastoma in the temozolomide era. JAMA Neurol. 2016;73:821.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Minniti G, et al. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. Int J Radiat Oncol. 2015;91:109–15.CrossRefGoogle Scholar
  35. 35.
    Perry JR, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376:1027–37.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Abdullah KG, et al. Factors associated with increased survival after surgical resection of glioblastoma in octogenarians. PLoS One. 2015;10:e0127202.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Ackerl M, et al. Outcome evaluation in glioblastoma patients older than 65 years: importance of individual assessment of treatment tolerance. Clin Neuropathol. 2014;33:399–406.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Álvarez de Eulate-Beramendi S, et al. Prognostic factors and survival study in high-grade glioma in the elderly. Br J Neurosurg. 2016;30:330–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Arrigo RT, Boakye M, Skirboll SL. Patterns of care and survival for glioblastoma patients in the veterans population. J Neuro-Oncol. 2012;106:627–35.CrossRefGoogle Scholar
  40. 40.
    Babu R, et al. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. J Neurosurg. 2016;124:998–1007.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Balducci M, et al. Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies. Med Oncol. 2012;29:3478–83.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Barker CA, et al. Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neuro-Oncol. 2012;109:391–7.CrossRefGoogle Scholar
  43. 43.
    Barnholtz-Sloan JS, et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg. 2008;108:642–8.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Chaichana KL, et al. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. J Neurosurg. 2011;114:587–94.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Chaichana KL, et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol. 2011;18:239–45.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Chang-Halpenny C. Elderly patients with glioblastoma multiforme treated with concurrent temozolomide and standard- versus abbreviated-course radiotherapy. Perm J. 2015;19:15–20.  https://doi.org/10.7812/TPP/14-083.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Chen Y-R, et al. National trends for reoperation in older patients with glioblastoma. World Neurosurg. 2018;113:e179–89.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Cloney M, et al. Frailty in geriatric glioblastoma patients: a predictor of operative morbidity and outcome. World Neurosurg. 2016;89:362–7.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Connon FV, Rosenthal MA, Drummond K. Glioblastoma multiforme in the very elderly. Neurosurg Rev. 2016;39:55–61.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    D’Amico RS, et al. The safety of surgery in elderly patients with primary and recurrent glioblastoma. World Neurosurg. 2015;84:913–9.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Ewelt C, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. J Neuro-Oncol. 2011;103:611–8.CrossRefGoogle Scholar
  52. 52.
    Gately L, Collins A, Murphy M, Dowling A. Age alone is not a predictor for survival in glioblastoma. J Neuro-Oncol. 2016;129:479–85.CrossRefGoogle Scholar
  53. 53.
    Grossman R, et al. Outcome of elderly patients undergoing awake-craniotomy for tumor resection. Ann Surg Oncol. 2013;20:1722–8.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Gulati S, Jakola AS, Johannesen TB, Solheim O. Survival and treatment patterns of glioblastoma in the elderly: a population-based study. World Neurosurg. 2012;78:518–26.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Hoffermann M, et al. Treatment results and outcome in elderly patients with glioblastoma multiforme--a retrospective single institution analysis. Clin Neurol Neurosurg. 2015;128:60–9.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64:628–34.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Iwamoto FM, Cooper AR, Reiner AS, Nayak L, Abrey LE. Glioblastoma in the elderly. Cancer. 2009;115:3758–66.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Iwamoto FM, et al. Prognosis and patterns of care in elderly patients with glioma. Cancer. 2009;115:5534–40.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Kita D, et al. Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology. 2009;33:17–22.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Konglund A, Helseth R, Lund-Johansen M, Helseth E, Meling TR. Surgery for high-grade gliomas in the aging. Acta Neurol Scand. 2013;128:185–93.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Kumabe T, et al. Treatment results of glioblastoma during the last 30 years in a single institute. Neurol Med Chir (Tokyo). 2013;53:786–96.CrossRefGoogle Scholar
  62. 62.
    Kurimoto M, et al. Prognostic factors in elderly patients with supratentorial malignant gliomas. Neurol Med Chir (Tokyo). 2007;47:543–9.CrossRefGoogle Scholar
  63. 63.
    Kushnir I, Tzuk-Shina T. Efficacy of treatment for glioblastoma multiforme in elderly patients (65+): a retrospective analysis. Isr Med Assoc J. 2011;13:290–4.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Lombardi G, et al. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). J Neuro-Oncol. 2015;125:359–67.CrossRefGoogle Scholar
  65. 65.
    Lorimer CF, Hanna C, Saran F, Chalmers A, Brock J. Challenges to treating older glioblastoma patients: the influence of clinical and tumour characteristics on survival outcomes. Clin Oncol. 2017;29:739–47.CrossRefGoogle Scholar
  66. 66.
    Mangiola A, et al. Glioblastoma multiforme in the elderly: a therapeutic challenge. J Neuro-Oncol. 2006;76:159–63.CrossRefGoogle Scholar
  67. 67.
    Mariniello G, et al. Glioblastoma in the elderly: the impact of advanced age on treatment and survival. J Neurol Surg Part A Cent Eur Neurosurg. 2014;75:276–81.CrossRefGoogle Scholar
  68. 68.
    Martinez R, Janka M, Soldner F, Behr R. Gross-total resection of malignant gliomas in elderly patients: implications in survival. Zentralbl Neurochir. 2007;68:176–81.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Muacevic A, Kreth FW. Quality-adjusted survival after tumor resection and/or radiation therapy for elderly patients with glioblastoma multiforme. J Neurol. 2003;250:561–8.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Mukerji N, et al. Treating high grade gliomas in the elderly: the end of ageism? J Neuro-Oncol. 2008;86:329–36.CrossRefGoogle Scholar
  71. 71.
    Noorbakhsh A, et al. Gross-total resection outcomes in an elderly population with glioblastoma: a SEER-based analysis. J Neurosurg. 2014;120:31–9.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Oh SW, et al. Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients. Acta Neurochir. 2014;156:641–51.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Oszvald Á, et al. Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg. 2012;116:357–64.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Piccirilli M, et al. Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years. Tumori. 2006;92:98–103.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Pontes L d B, et al. Patterns of care and outcomes in elderly patients with glioblastoma in Sao Paulo, Brazil: a retrospective study. J Geriatr Oncol. 2013;4:388–93.CrossRefGoogle Scholar
  76. 76.
    Pretanvil J-A, Salinas IQ, Piccioni DE. Glioblastoma in the elderly: treatment patterns and survival. CNS Oncol. 2017;6:19–28.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Rigamonti A, et al. Pattern of care and outcome in elderly patients with glioblastoma: data in 151 patients from 3 Lombardia hospitals. J Neurol Sci. 2017;378:3–8.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Scoccianti S, et al. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the central nervous system study group of Airo (Italian Association of Radiation Oncology). Neurosurgery. 2010;67:446–58.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Scott JG, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neuro-Oncology. 2011;13:428–36.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Shah BK, Bista A, Sharma S. Survival trends in elderly patients with glioblastoma in the United States: a population-based study. Anticancer Res. 2016;36:4883–6.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Stark AM, Hedderich J, Held-Feindt J, Mehdorn HM. Glioblastoma–the consequences of advanced patient age on treatment and survival. Neurosurg Rev. 2007;30:56–61.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Stummer W, et al. Extent of resection and survival in glioblastoma multiforme. Neurosurgery. 2008;62:564–76.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Tanaka S, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. J Neurosurg. 2013;118:786–98.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Tsang DS, et al. Survival outcomes in elderly patients with glioblastoma. Clin Oncol. 2015;27:176–83.CrossRefGoogle Scholar
  85. 85.
    Uzuka T, et al. Treatment outcomes in glioblastoma patients aged 76 years or older: a multicenter retrospective cohort study. J Neuro-Oncol. 2014;116:299–306.CrossRefGoogle Scholar
  86. 86.
    Uzuka T, Aoki H, Natsumeda M, Takahashi H, Fujii Y. Effectiveness of maximal safe resection for glioblastoma including elderly and low Karnofsky performance status patients: retrospective review at a single institute. Neurol Med Chir (Tokyo). 2012;52:570–6.CrossRefGoogle Scholar
  87. 87.
    Whittle IR, Basu N, Grant R, Walker M, Gregor A. Management of patients aged >60 years with malignant glioma: good clinical status and radiotherapy determine outcome. Br J Neurosurg. 2002;16:343–7.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Zachenhofer I, et al. Overall survival and extent of surgery in adult versus elderly glioblastoma patients: a population based retrospective study. Wien Klin Wochenschr. 2011;123:364–8.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Zhang C, et al. Analysis of treatment tolerance and factors associated with overall survival in elderly patients with glioblastoma. World Neurosurg. 2016;95:77–84.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Zinn PO, Colen RR, Kasper EM, Burkhardt J-K. Extent of resection and radiotherapy in GBM: a 1973 to 2007 surveillance, epidemiology and end results analysis of 21,783 patients. Int J Oncol. 2013;42:929–34.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Joseph H. McAbee
    • 1
    Email author
  • Aida K. Golahmadi
    • 2
  • Colin Watts
    • 3
  1. 1.Department of Clinical Neurosciences, Cambridge Centre for Brain RepairUniversity of CambridgeCambridgeUK
  2. 2.School of Medicine, Imperial College London and Imperial College NHS TrustLondonUK
  3. 3.Birmingham Brain Cancer ProgramInstitute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of BirminghamBirminghamUK

Personalised recommendations